Katherine Dinan
Family · Daytona Beach, FLNPI 1487285953
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $445 of the $540 with a category attached, or 82.4%. 12 manufacturers reported payments, led by Johnson & Johnson at 24.7% of the total. Reporting peaked in 2022 at $263 and has fallen 56.2% since, to $115 in 2025.
Across 22 payments — averaging $24.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$133
- Medical Device Business Services, Inc.$95
- Novo Nordisk$67
- Vertex$50
- Integra Lifesciences Corporation$43
- Endo Pharmaceuticals Inc.$38
- plus $113 from 6 others
What the payments were for
- Travel & lodging$9518%
- Food & beverage$44582%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 5 | $133 |
| Medical Device Business Services, Inc. | 1 | $95 |
| Novo Nordisk | 4 | $67 |
| Vertex | 2 | $50 |
| Integra Lifesciences Corporation | 2 | $43 |
| Endo Pharmaceuticals Inc. | 2 | $38 |
| Intuitive Surgical | 1 | $29 |
| Davol Inc. | 1 | $22 |
| Aroa Biosurgery Incorporated | 1 | $19 |
| Teleflex LLC | 1 | $16 |
| Heron Therapeutics, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
How this compares
$540 in reported general payments places this provider in the 55th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nystatin | 14 | $275 |
| Omeprazole | 25 | $84 |
Paid to pharmacies, not to this prescriber.
Other family in Daytona Beach
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.